Cardima completes atrial fibrillation study:
This article was originally published in Clinica
Cardima, a US developer of microcatheter systems for diagnosing and treating abnormal heart rhythms, has completed a feasibility study of a device for treating atrial fibrillation. The ten-patient study took place at three US hospitals and the Fremont, California-based company plans to submit the results to the FDA by the end of the year to expand the trial to ten US centres. The device is already CE-marked in Europe.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.